“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Pancreatic Cancer News
PANCREATIC CANCER ADVISOR
Pancreatic Cancer News
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
Treatment Options for Pancreatic Neuroendocrine Tumors
In the management of PNETs it is important to differentiate between functional and nonfunctional PNETs in order to determine the course of treatment.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Improving Cancer Pain Management Amid the Opioid Crisis
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
A New Trend in Drug Development: Leveraging Data from Expanded Access
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
Evidence Suggests B Cells Play a Role in Immunotherapy Response
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
The Unexpected Costs of Cancer Treatment: Out-of-Network Billing
The cancer field is not immune to the challenges of out-of-network and surprise billing.
Addition of PEGPH20 to Frontline Chemotherapy Did Not Improve Clinical Outcomes in Pancreatic Cancer Subgroup
Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.
Addition of Pegilodecakin to FOLFOX Did Not Improve OS in Metastatic Pancreatic Cancer
Promising results from an earlier-phase study of FOLFOX plus pegilodecakin in metastatic PDAC refractory to gemcitabine provided a rationale for this study.
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
Effects of Surgeon Volume, Nurse-to-Patient Ratio on Potential Complications With Pancreaticoduodenectomy
Although higher nurse-to-patient ratios ensure good outcomes for patients undergoing pancreaticoduodenectomy, PD-specific surgeon volume has a greater effect on risks of complications for these patients.
PALB2 Linked to Increased Risk for Breast, Ovarian, and Pancreatic Cancer
Germline PALB2 pathogenic variants were associated with an increased risk of female or male breast cancer, as well as ovarian and pancreatic cancer.
Lynparza Gains Pancreatic Cancer Indication
Results showed that Lynparza had a significantly longer median PFS compared with placebo (7.4 months vs 3.8 months).
Resistance to Immune Checkpoint Inhibition in Pancreatic Cancer
Research presented at SITC 2019 looks at 2 different mechanisms for resistance to immune checkpoint inhibition in pancreatic ductal adenocarcinoma.
Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities
The chance of missing a disease-causing variant can be as high as 100% across some groups.
When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
